Carna Biosciences, Inc. (TYO:4572)
427.00
-5.00 (-1.16%)
Sep 16, 2026, 3:09 PM JST
Carna Biosciences Revenue
Carna Biosciences had revenue of 217.37M JPY in the quarter ending June 30, 2026, with 101.91% growth. This brings the company's revenue in the last twelve months to 729.00M, up 27.45% year-over-year. In the year 2025, Carna Biosciences had annual revenue of 579.00M, down -8.96%.
Revenue (ttm)
729.00M
Revenue Growth
+27.45%
P/S Ratio
12.53
Revenue / Employee
11.95M
Employees
61
Market Cap
9.14B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 579.00M | -57.00M | -8.96% |
| Dec 31, 2024 | 636.00M | -989.00M | -60.86% |
| Dec 31, 2023 | 1.63B | 239.00M | 17.24% |
| Dec 31, 2022 | 1.39B | -631.00M | -31.28% |
| Dec 31, 2021 | 2.02B | 884.00M | 78.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.14B |
| StemCell Institute | 2.81B |
| Immuno-Biological Laboratories | 1.08B |
| OncoTherapy Science | 777.00M |
| Nano Holdings | 202.00M |
| CellSeed | 161.00M |
| ADR Biomedical Holdings | 101.00M |
| Kubota Pharmaceutical Holdings | 16.00M |